Drug updated on 12/11/2024
Dosage Form | Tablet (oral; 150 mg) |
Drug Class | Triterpenoid antifungals |
Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- Indicated for the treatment of adult and post-menarchal pediatric females for vulvovaginal candidiasis (VVC)
- Indicated for the treatment of adult and post-menarchal pediatric females for reduction in the incidence of recurrent vulvovaginal candidiasis (RVVC).
Latest News
Summary
- This summary is based on the review of one systematic review/meta-analysis. [1]
- Ibrexafungerp demonstrated superior clinical cure rates compared to fluconazole/placebo, with a relative risk (RR) of 1.33 [1.07, 1.66], indicating a significantly higher likelihood of clinical cure in patients treated with ibrexafungerp.
- The mycological eradication rate for ibrexafungerp was also higher than fluconazole/placebo (RR = 1.72 [1.00, 2.95]), reflecting a greater capacity for eliminating the fungal infection.
- Ibrexafungerp showed an overall success ratio (RR = 1.64 [0.92, 2.92]), demonstrating better outcomes in clinical success when compared to fluconazole/placebo in treating vulvovaginal candidiasis caused by C. albicans.
- The duration of treatment-emergent adverse events (TEAEs), including nausea and diarrhea, was significantly longer in patients treated with ibrexafungerp compared to those treated with fluconazole/placebo.
- No serious adverse safety concerns were highlighted in the source, but ibrexafungerp was associated with a higher incidence and longer duration of gastrointestinal-related TEAEs compared to fluconazole/placebo.
- The population types and subgroup considerations section states that the studies included a total of 880 patients diagnosed with vulvovaginal candidiasis. There is no specific information available on different population types or subgroups (e.g., age, gender, comorbidities) in the reviewed studies, and the findings appear to apply to the general study population.
Product Monograph / Prescribing Information
Document Title | Year | Source |
---|---|---|
Brexafemme (ibrexafungerp) Prescribing Information. | 2022 | SCYNEXIS Inc., Jersey City, NJ |
Systematic Reviews / Meta-Analyses
Document Title | Year | Source |
---|---|---|
Efficacy and safety of ibrexafungerp in the treatment of vulvovaginal candidiasis: A meta-analysis of randomized controlled trials. | 2024 | Heliyon |
Clinical Practice Guidelines
Document Title | Year | Source |
---|---|---|
Treatment of Vulvovaginal Candidiasis-An Overview of Guidelines and the Latest Treatment Methods. | 2023 | Journal of Clinical Medicine |
Vulvovaginal Candidiasis: A Review of the Evidence for the 2021 Centers for Disease Control and Prevention of Sexually Transmitted Infections Treatment Guidelines. | 2022 | Clinical Infectious Diseases |